Injection:Article Title: Sulfated polysaccharide prevents senescent adipocyte-driven osteonecrosis by stem cell fate reprogramming
Article Snippet: .. After each injection, the injection site was sealed with bone wax to prevent leakage, and mice received subcutaneous injections of the antibiotic clindamycin (45 mg/kg, MCE, China) to prevent infection. .. Other drugs and compounds used in this study included: GW9662 (MCE, HY-16578; intraperitoneal injection, 1 mg/kg body weight/day, administered continuously for 4 weeks), T0070907 (Selleck, S2871; intraperitoneal injection, 2 mg/kg body weight/day, administered continuously for 4 weeks), rapamycin (MCE, HY-10219; subcutaneous injection, 3 mg/kg body weight/day, administered continuously for 4 weeks), Rosiglitazone (MCE, HY-17386; oral gavage, 3 mg/kg body weight/day, administered continuously for 2 weeks), LY294002 (Selleck, S1105; intraosseous injection, 10 μM, 5 μL per dose per week, administered for 1 or 4 weeks), DMH1 (Selleck, S7146; intraperitoneal injection, 5 mg/kg body weight/day, administered continuously for 4 weeks), Noggin (PeproTech, 250-38; intraosseous injection, 50 ng per dose, twice per week, administered for 2 or 4 weeks), LDN-193189 (Selleck, S2618; intraperitoneal injection, 3 mg/kg body weight/day, administered for 1 or 4 weeks), IGF-1 (PeproTech, 250-19; intraosseous injection, 4 μg per dose per week, administered for 2 weeks), IGF-1 neutralizing antibody (R&D Systems, AF-791; intraosseous injection, 2 μg per dose, twice per week, administered for 2 or 4 weeks), VEGF neutralizing antibody (R&D Systems, AF-493-NA; intraosseous injection, 2 μg per dose, twice per week, administered for 4 weeks), PDGF-AA neutralizing antibody (R&D Systems, AF-221-NA; intraosseous injection, 2 μg per dose, twice per week, administered for 4 weeks), PDGF-BB neutralizing antibody (R&D Systems, AF-220-NA; intraosseous injection, 2 μg per dose, twice per week, administered for 4 weeks), TGF-β1 neutralizing antibody (R&D Systems, MAB2401; intraosseous injection, 2 μg per dose, twice per week, administered for 4 weeks), TGF-β2 neutralizing antibody (R&D Systems, AB-112-NA; intraosseous injection, 2 μg per dose, twice per week, administered for 4 weeks).
Infection:Article Title: Sulfated polysaccharide prevents senescent adipocyte-driven osteonecrosis by stem cell fate reprogramming
Article Snippet: .. After each injection, the injection site was sealed with bone wax to prevent leakage, and mice received subcutaneous injections of the antibiotic clindamycin (45 mg/kg, MCE, China) to prevent infection. .. Other drugs and compounds used in this study included: GW9662 (MCE, HY-16578; intraperitoneal injection, 1 mg/kg body weight/day, administered continuously for 4 weeks), T0070907 (Selleck, S2871; intraperitoneal injection, 2 mg/kg body weight/day, administered continuously for 4 weeks), rapamycin (MCE, HY-10219; subcutaneous injection, 3 mg/kg body weight/day, administered continuously for 4 weeks), Rosiglitazone (MCE, HY-17386; oral gavage, 3 mg/kg body weight/day, administered continuously for 2 weeks), LY294002 (Selleck, S1105; intraosseous injection, 10 μM, 5 μL per dose per week, administered for 1 or 4 weeks), DMH1 (Selleck, S7146; intraperitoneal injection, 5 mg/kg body weight/day, administered continuously for 4 weeks), Noggin (PeproTech, 250-38; intraosseous injection, 50 ng per dose, twice per week, administered for 2 or 4 weeks), LDN-193189 (Selleck, S2618; intraperitoneal injection, 3 mg/kg body weight/day, administered for 1 or 4 weeks), IGF-1 (PeproTech, 250-19; intraosseous injection, 4 μg per dose per week, administered for 2 weeks), IGF-1 neutralizing antibody (R&D Systems, AF-791; intraosseous injection, 2 μg per dose, twice per week, administered for 2 or 4 weeks), VEGF neutralizing antibody (R&D Systems, AF-493-NA; intraosseous injection, 2 μg per dose, twice per week, administered for 4 weeks), PDGF-AA neutralizing antibody (R&D Systems, AF-221-NA; intraosseous injection, 2 μg per dose, twice per week, administered for 4 weeks), PDGF-BB neutralizing antibody (R&D Systems, AF-220-NA; intraosseous injection, 2 μg per dose, twice per week, administered for 4 weeks), TGF-β1 neutralizing antibody (R&D Systems, MAB2401; intraosseous injection, 2 μg per dose, twice per week, administered for 4 weeks), TGF-β2 neutralizing antibody (R&D Systems, AB-112-NA; intraosseous injection, 2 μg per dose, twice per week, administered for 4 weeks).
Control:Article Title: Comparative Impacts of Oral Amoxicillin, Azithromycin, and Clindamycin on Gut Microbiota and Intestinal Homeostasis.
Article Snippet: .. At the 5-day time point, the Control subgroup received 0.9% NaCl (5 μL/g body weight) via oral gavage twice daily for 5 days (10 a.m. and 6 p.m.); the Azithromycin (Azit) subgroup received azithromycin (MedChemExpress, Shanghai, China„ HY-17506A) via oral gavage once daily at 10 a.m. (102.5 mg/kg on day 1, 51.25 mg/kg from days 2–5; 10 μL/g body weight, with concentrations 10.25 mg/mL and 5.125 mg/mL respectively); and the Clindamycin (Clin) subgroup received clindamycin (MedChemExpress, Shanghai, China„ HY-B1358) at 246 mg/kg/day (24.6 mg/mL, 5 μL/g body weight) via oral gavage twice daily for 5 days (10 a.m. and 6 p.m.). ..
Article Title: Comparative Impacts of Oral Amoxicillin, Azithromycin, and Clindamycin on Gut Microbiota and Intestinal Homeostasis
Article Snippet: .. At the 5-day time point, the Control subgroup received 0.9% NaCl (5 μL/g body weight) via oral gavage twice daily for 5 days (10 a.m. and 6 p.m.); the Azithromycin (Azit) subgroup received azithromycin (MedChemExpress, Shanghai, China,, HY-17506A) via oral gavage once daily at 10 a.m. (102.5 mg/kg on day 1, 51.25 mg/kg from days 2–5; 10 μL/g body weight, with concentrations 10.25 mg/mL and 5.125 mg/mL respectively); and the Clindamycin (Clin) subgroup received clindamycin (MedChemExpress, Shanghai, China,, HY-B1358) at 246 mg/kg/day (24.6 mg/mL, 5 μL/g body weight) via oral gavage twice daily for 5 days (10 a.m. and 6 p.m.). ..
|
MedChemExpress is a verified supplier 
MedChemExpress manufactures this product 